Journal of Bone and Mineral Metabolism最新文献_第7页

Sequential and combination therapy with romosozumab. romosozumab序贯和联合治疗。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2025-03-01 DOI: 10.1007/s00774-025-01590-2

Tomonori Kobayakawa

{"title":"Sequential and combination therapy with romosozumab.","authors":"Tomonori Kobayakawa","doi":"10.1007/s00774-025-01590-2","DOIUrl":"10.1007/s00774-025-01590-2","url":null,"abstract":"The introduction of the bone-forming agent romosozumab has led to a dramatic improvement in osteoporosis treatment. While bisphosphonates remain the most commonly used drugs for the treatment of osteoporosis, it is recommended that patients at high risk of fractures initially receive bone-forming agents, followed by sequential treatment with bone resorption inhibitors. Romosozumab, an anti-sclerostin antibody, is an osteoporosis medication with both bone formation-stimulating and bone resorption-inhibiting properties, demonstrating significant efficacy in increasing bone mineral density and reducing fracture risk. However, due to the limited 12-month initial treatment period, sequential therapy with other osteoporosis medications is necessary following the completion of romosozumab administration. Due to the current lack of sufficient evidence regarding the use of romosozumab in sequential and combination therapies, this review aims to evaluate the efficacy of romosozumab as a sequential treatment, its effectiveness in combination with other agents, and its role in reducing new fragility fractures and increasing bone mineral density following sequential therapy after romosozumab. This review will summarize clinical trials and real-world data, providing valuable information to guide treatment decisions.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"10-17"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular safety of osteoanabolic agents. 骨合成代谢药物的心血管安全性。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2025-01-17 DOI: 10.1007/s00774-025-01580-4

Yasuhiro Takeuchi

{"title":"Cardiovascular safety of osteoanabolic agents.","authors":"Yasuhiro Takeuchi","doi":"10.1007/s00774-025-01580-4","DOIUrl":"10.1007/s00774-025-01580-4","url":null,"abstract":"Purpose: Several osteoanabolic agents have been developed to build new bone more efficiently than anti-resorptive drugs. Among them, romosozumab, an anti-sclerostin antibody, is a potent pharmacological tool to prevent fractures in osteoporosis patients. The efficacy of romosozumab in preventing osteoporotic fractures is robust. However, there remains a concern about increased cardiovascular (CV) adverse events related to romosozumab. Available data have been reviewed to address this concern.Methods: Published articles on romosozumab of which pivotal randomized controlled trials (RCTs), meta-analyses of RCTs, pharmacovigilance investigations, and retrospective observational clinical studies using real-world data were collected through PubMed and other available tools.Results: Meta-analyses of RCTs of romosozumab compared to placebo and other anti-osteoporosis drugs have left room for controversy in the CV safety of romosozumab. Investigations of the real-world data also provide no conclusive evidence in this issue.Conclusion: We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"26-32"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osteoanabolic agents for fracture prevention: bone building beyond bone protection. 预防骨折的骨合成代谢剂：超越骨保护的骨建设。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 DOI: 10.1007/s00774-025-01591-1

Yasuhiro Takeuchi, Hiroshi Hagino

引用次数: 0

Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. 特立帕肽、阿帕帕肽和罗莫索单抗对绝经后骨质疏松症的临床效果。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2024-07-15 DOI: 10.1007/s00774-024-01536-0

Kosuke Ebina, Yuki Etani, Takaaki Noguchi, Ken Nakata, Seiji Okada

{"title":"Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.","authors":"Kosuke Ebina, Yuki Etani, Takaaki Noguchi, Ken Nakata, Seiji Okada","doi":"10.1007/s00774-024-01536-0","DOIUrl":"10.1007/s00774-024-01536-0","url":null,"abstract":"In the management of osteoporosis, anti-resorptive agents serve as a primary therapeutic approach. However, in cases where individuals exhibit an increased susceptibility to fractures, such as those characterized by severe low bone mass or a history of vertebral or hip fractures that markedly diminish life expectancy, the immediate reduction of fracture risk through the administration of osteoanabolic agents could be beneficial. Teriparatide, available in daily, once-weekly, or twice-weekly dosages, along with abaloparatide and romosozumab, constitutes a trio of such agents. Each of these medications is defined by unique characteristics, distinct efficacy profiles, and specific adverse effects. There is growing evidence to suggest that these agents have a superior effect on enhancing bone mineral density and reducing fracture incidence when compared to traditional bisphosphonate therapies. Nonetheless, their employment demands thorough consideration of clinical indications, which includes evaluating economic factors, the frequency of injections required, and the potential for adverse effects. The objective of this review is to consolidate the current evidence focusing primarily on the efficacy of these agents, with the goal of enhancing understanding and aiding in making more informed treatment decisions, particularly for those individuals who are at an elevated risk of fractures.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"3-9"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

List of reviewers 2024. 审稿人名单2024。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-12-04 DOI: 10.1007/s00774-024-01565-9

引用次数: 0

Journal of Bone and Mineral Metabolism Best Paper Award 2024. 骨与矿物质代谢杂志2024年最佳论文奖。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-11-30 DOI: 10.1007/s00774-024-01566-8

引用次数: 0

Incidence of four major osteoporotic fragility fractures among older individuals in Sado, Japan, in 2020. 2020 年日本佐渡地区老年人四种主要骨质疏松性脆性骨折的发病率。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-11-01 Epub Date: 2024-07-08 DOI: 10.1007/s00774-024-01529-z

Norio Imai, Asami Nozaki, Yugo Shobugawa, Kentaro Higuchi, Yoshihiro Suda, Takeo Oinuma, Hayato Suzuki, Yoji Horigome, Hiroyuki Kawashima

{"title":"Incidence of four major osteoporotic fragility fractures among older individuals in Sado, Japan, in 2020.","authors":"Norio Imai, Asami Nozaki, Yugo Shobugawa, Kentaro Higuchi, Yoshihiro Suda, Takeo Oinuma, Hayato Suzuki, Yoji Horigome, Hiroyuki Kawashima","doi":"10.1007/s00774-024-01529-z","DOIUrl":"10.1007/s00774-024-01529-z","url":null,"abstract":"Introduction: This study compared the 2020 incidence of fragility fractures in Sado City with those from 2004 to 2015.Materials and methods: Data from patients aged ≥ 60 years living in Sado City with fragility fractures in the hip, vertebral, distal radius, and proximal humerus between January 1 and December 31, 2020, were collected. We examined the number and incidence of four types of osteoporotic fractures in the older population aged ≥ 60 years living in Sado City in 2020. We compared the results with those of the 2004, 2010, and 2015 surveys, examining the temporal change and trend in the incidence of the four fracture types in this population. We investigated the use rate of anti-osteoporotic medications and the relationship between their administration and the occurrence of fragility fractures.Results: The age-specific incidence of hip fractures slightly decreased from 2015. However, the incidence of the other three fractures slightly increased, although the difference was not statistically significant. The incidence of hip fractures markedly increased in the 80 s. In 2020, the percentage of patients taking anti-osteoporotic agents before the occurrence of fractures decreased to 12.4% from 14.5% in 2015; it increased from 4% in 2004 to 7.6% in 2010.Conclusion: The 2020 incidence of the four fractures did not decrease, and the percentage of patients receiving anti-osteoporotic agents did not increase. A higher frequency of osteoporosis treatment is necessary to reduce the incidence of fragility fractures. We recommend using anti-osteoporotic agents to prevent hip fractures among individuals in their mid-70 s and above.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"647-652"},"PeriodicalIF":2.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gender differences between smoking and the risk of hip fracture. 吸烟与髋部骨折风险之间的性别差异。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-11-01 Epub Date: 2024-09-26 DOI: 10.1007/s00774-024-01546-y

Yilun Tang, Yan Xu, Jinhui Song, Chen Zhang, Run Tian, Kunzheng Wang, Pei Yang

引用次数: 0

Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL. 双膦酸盐和地诺单抗治疗对日本乳腺癌 AIBL 患者 TBS 的影响

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-11-01 Epub Date: 2024-08-13 DOI: 10.1007/s00774-024-01542-2

Emi Onuma, Shin Saito, Taku Tsuburai, Hiromi Yoshikata, Shoko Adachi, Shinya Yamamoto, Kazutaka Narui, Tomonari Hayama, Mariko Murase, Taichi Mizushima, Etsuko Miyagi, Hideya Sakakibara, Ryoko Asano

{"title":"Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL.","authors":"Emi Onuma, Shin Saito, Taku Tsuburai, Hiromi Yoshikata, Shoko Adachi, Shinya Yamamoto, Kazutaka Narui, Tomonari Hayama, Mariko Murase, Taichi Mizushima, Etsuko Miyagi, Hideya Sakakibara, Ryoko Asano","doi":"10.1007/s00774-024-01542-2","DOIUrl":"10.1007/s00774-024-01542-2","url":null,"abstract":"Introduction: Bisphosphonates and denosumab increase bone mineral density (BMD) for osteoporosis treatment in patients with aromatase inhibitor-associated bone loss (AIBL). This study aimed to directly compare bisphosphonates with denosumab in treating patients with AIBL and to determine the effect of denosumab on the trabecular bone score (TBS).Materials and methods: Thirty-nine patients with AIBL receiving osteoporosis treatment (21 in the bisphosphonates group and 18 in the denosumab group) were retrospectively evaluated for changes in lumbar spine and femoral BMD, lumbar spine bone quality (assessed by TBS), and blood bone metabolic markers. The Mann-Whitney and Wilcoxon tests were used for statistical evaluation.Results: After 24 months of treatment, the lumbar spine BMD change rate was 5.82 ± 1.10% with bisphosphonates and 10.49 ± 1.20% with denosumab, with the change rate of denosumab significantly increasing over that of bisphosphonates. The change rate in femoral BMD was 2.69 ± 1.16% with bisphosphonates and 2.95 ± 1.26% with denosumab, with no significant difference between the two groups. The rate of decrease in tartrate-resistant acid phosphatase isoform 5b was significantly higher in the denosumab group. The change rate in TBS at 24 months of treatment was 0.53 ± 1.26% in the bisphosphonates group and 1.08 ± 1.33% in the denosumab group, with no significant difference between the two groups. After 24 months, TBS remained stable.Conclusion: Both bisphosphonates and denosumab may increase BMD, improve bone metabolism, and inhibit bone quality loss in patients with AIBL.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"699-709"},"PeriodicalIF":2.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer. 单次输注 5 毫克唑来膦酸预防绝经后乳腺癌妇女骨质流失和骨折的疗效。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-11-01 Epub Date: 2024-09-30 DOI: 10.1007/s00774-024-01552-0

Han-Sang Baek, Kabsoo Shin, Jinyoung Kim, Chaiho Jeong, Jeongmin Lee, Yejee Lim, Ki-Hyun Baek, Jeonghoon Ha

{"title":"Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer.","authors":"Han-Sang Baek, Kabsoo Shin, Jinyoung Kim, Chaiho Jeong, Jeongmin Lee, Yejee Lim, Ki-Hyun Baek, Jeonghoon Ha","doi":"10.1007/s00774-024-01552-0","DOIUrl":"10.1007/s00774-024-01552-0","url":null,"abstract":"Introduction: Chemotherapy-induced bone loss (CTIBL) is common among breast cancer patients, requiring comprehensive assessment and intervention. Zoledronic acid, a strong inhibitor of bone resorption, is effective in CTIBL management, though information on dosing and intervals, particularly the efficacy of the 5 mg annual dose for osteoporosis in breast cancer patients, is limited.Materials and methods: In this 12-month prospective observational study, 85 breast cancer patients were divided into three groups: 17 received no treatment, 17 received tamoxifen, and 51 received anastrozole or letrozole (AI). Post-surgery, patients were administered a single 5 mg dose of zoledronic acid and monitored over 12 months for changes in bone mineral density (BMD), fracture rates, and biochemical markers.Results: Initially, the AI group was the oldest, averaging 59.1 ± 8.7 years. At baseline, no significant differences in variables, except age, were observed. After 12 months, BMD increased in all groups following a single zoledronic acid dose, with the smallest increase in the AI group at the lumbar spine: no treatment (2.4% ± 6.1%), tamoxifen (2.6% ± 3.4%), AI (0.6% ± 14.5%) (p = 0.778). CTx and P1NP levels were consistently suppressed up to 12 months post-treatment, with smaller reductions in the AI group. There were no significant differences in fracture or bone metastasis rates among groups.Conclusion: A single infusion of 5 mg zoledronic acid was effective in increasing bone density in breast cancer patients. However, AI-treated patients showed less improvement in vertebral bone mineral density and biochemical markers. Further long-term studies with larger cohorts are needed.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"720-727"},"PeriodicalIF":2.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0